Infections Associated With the Use of Alemtuzumab

Samsung Medical Center182 enrolled

Overview

The aim of this study is to propose infection prophylaxis from Asian multinational retrospective analysis of infectious complications in patients who were treated with alemtuzumab

Study Type

OBSERVATIONAL

Enrollment

182

Conditions

Patients Treated With Alemtuzumab

Eligibility

Sex: ALLMin age: 15 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients received alemtuzumab as a treatment for hematologic malignancy ex. non-Hodgkin lymphoma Acute myeloid leukemia Aplastic anemia Exclusion Criteria: * Patients did not receive alemtuzumab

Locations (5)

Queen Mary Hospital

Hong Kong, China

Cipto Mangunkusumo General Hospital

Jakarta, Indonesia

Samsung Medical Center

Seoul, South Korea

National Taiwan University Hospital

Teipei, Taiwan

Chulalongkorn University

Outcomes

Primary Outcomes

Infectious event

Any infectious complication occurred within one year after the use of alemtuzumab

Time frame: one year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.